 |
|
|
| |
Safety & Efficacy of Raltegravir Over 3-5 Years in Patients Co-infected With HIV and Hepatitis B and/or C Virus
|
| |
| |
Reported by Jules Levin
52nd ICAAC Sept 9-12 2012 SF
Jürgen Rockstroh1, Peter Sklar2, Jing Zhao2, Hedy Teppler2, Charlotte Harvey2, Kim Strohmaier2, Randi Leavitt2, and Bach-Yen Nguyen2
1University of Bonn, Bonn-Venusberg, Germany; 2Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA
CONCLUSIONS
· In HIV-infected patients with Hepatitis B and/or Hepatitis C co-infection, RAL in combination treatment was efficacious
-- Through 5 years in treatment-naive patients
-- Through 3 years in treatment-experienced patients
· RAL was generally well tolerated in HIV-infected patients with Hepatitis B and/or Hepatitis C co-infection
-- Grade 2-4 liver enzyme elevations were more common in co-infected patients than in those with HIV mono-infection, irrespective
of treatment group
-- The majority of grade 3 and grade 4 liver enzyme elevations occurred during the first year of treatment
|
| |
|
|
|
|
|
